Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP

Molecular Cancer Research

Volumn 12, Issue 12, 2014, Pages 1755-1766

  Chao, Olivia S ^a   Goodman, Oscar B ^a,b  

^a ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b Department of Hematology Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; RAD51 PROTEIN; VORINOSTAT; BRCA1 PROTEIN, HUMAN; ENZYME INHIBITOR; HYDROXAMIC ACID; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; RAD51 PROTEIN, HUMAN;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL CYCLE; CELL CYCLE CHECKPOINT; CELL FRACTIONATION; CELL VIABILITY; CELL VIABILITY ASSAY; CLONOGENESIS; CLONOGENIC ASSAY; COMET ASSAY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; MTT ASSAY; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSFORMED CELL; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DNA REPAIR; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

BRCA1 PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; RAD51 RECOMBINASE;

EID: 84919330009     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0173     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. DeVita VT, Lawrence TS, Rosenberg SA. Cancer: principles and practice of oncology-advances in oncology: Lippincott Williams & Wilkins, Philadelphia, PA; 2010.
3. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014;120:818-23.
4. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res 2004;64:8526-33.
5. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
6. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
7. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
8. Dobzhansky T. Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura. Genetics 1946;31:269-90.
9. Beltran H, Yelensky R, FramptonGM, Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013;63:920-6.
10. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
11. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous Tcell lymphoma. Oncologist 2007;12:1247-52.
12. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102: 673-8.
13. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo . Cancer Res 2000;60:5165-70.
14. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009;115:5541-9.
15. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
16. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005;62:223-9.
17. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE 2010;5: e11208.
18. Weberpals JI, O'Brien AM, Niknejad N, Garbuio KD, Clark-Knowles KV, Dimitroulakos J. The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells. Cancer Cell Int 2011;11:29.
19. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SGT, et al. Histone deacetylase inhibitor treatment induces "BRCAness" and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 2014;5:5637-50.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
21. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676-82.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
23. Yamamoto N, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, et al. A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci 2012;103:504-9.
24. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
25. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-68.
26. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/proapoptotic dual-role proteins in five major DNA repair pathways: failsafe protection against carcinogenesis. Mutat Res 2002;511: 145-78.
27. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Speci fic killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7.
28. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
29. Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL. Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer 2010;10:4.
30. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor inducesDNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A 2010;107:14639-44.
31. Long J, Zhao J, Yan Z, Liu Z, Wang N. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40. Int J Cancer 2009;124:1235-44.
32. Lee YJ, Won AJ, Lee J, Jung JH, Yoon S, Lee BM, et al. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci 2012;9:881-93.
33. Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011;2011:830260.
34. Sampath D, Zecevic A, Ewald B, Hayes M, Liu C, Marcucci G, et al. Panobinostat, an oral pan-histone deacetylase (HDAC) inhibitor activates a microrna signature that targets Rad51 to attenuate homologous DNA repair and sensitize AML cells to sapacitabine. Blood 2013;122:822.
35. Bhalla KN, Rao R, Sharma P, Das Gupta S, Chauhan L, Stecklein S, et al. Treatment with histone deacetylase inhibitors creates 'BRCAness' and sensitizes human triple negative breast cancer cells to PARP inhibitors and cisplatin. Cancer Res 2012;72:S3-7.
36. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gam-ma-H2AX foci. Mol Cancer Ther 2006;5:1967-74.
37. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A 2010;107:2201-6.
38. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005;65:11597-604.
39. Bindra RS, Glazer PM. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 2007;26:2048-57.
40. Lu Y, Chu A, Turker MS, Glazer PM. Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol Cell Biol 2011;31:3339-50.
41. Krishnakumar R, Kraus WL. PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell 2010;39:736-49.
42. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001;29:1534-8.
43. Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 2009;8:203-13.
44. Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 2009;55:696-704.
45. Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair 2008;7:686-93.
46. Qiao GB, WuYL, Yang XN, Zhong WZ, Xie D, Guan XY, et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 2005;93:137-43.
47. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 2000;88:907-13.
48. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, Bishop DK. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-defi cient breast tumors. Cancer Res 2007;67:9658-65.
49. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013;14:882-92.